Test results concerning platelet behavior in vitro, particularly aggregation, are frequently abnormal in diabetic patients. The concept has therefore arisen that platelet hyper-reactivity is one factor contributing to diabetic microangiopathy. We report here the antiplatelet effect of beraprost sodium, a chemically stable prostaglandin I2 analogue made in Japan, in 6 diabetic patients. Platelet aggregation induced by adenosine 5'-diphosphate (10 microM) after administration of beraprost sodium (40 micrograms every 8 h for 14 days) was significantly decreased as compared with levels before beraprost sodium administration. These results indicate the possibility that the occurrence of vascular complications in diabetes mellitus can be suppressed by long-term administration of beraprost sodium.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of Beraprost on Intestinal Microcirculation and Barrier Function in a Mouse Model of Renal Failure.
Microcirculation
November 2024
Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Objective: Endothelial dysfunction plays an important role in the pathogenesis of chronic kidney disease. Prostacyclin (PGI), an endothelial cell-produced endogenous prostaglandin, plays a crucial role in maintaining endothelial function. However, its effects on intestinal microcirculation and barrier function are not fully understood.
View Article and Find Full Text PDFSwitching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study).
Pharmaceuticals (Basel)
April 2024
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a novel selective prostacyclin receptor agonist, within a Japanese cohort. Employing a multicenter, open-label, prospective design, 25 PAH patients inadequately managed on beraprost were switched to selexipag.
View Article and Find Full Text PDFComparative Study of Cardiovascular Effects of Selected Pulmonary Vasodilators in Canine Models of Mitral Valve Disease.
Biology (Basel)
April 2024
Laboratory of Veterinary Internal Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, Tokyo 180-8602, Japan.
Article Synopsis
- Previous research confirmed that oral pulmonary vasodilators are beneficial for treating pulmonary hypertension (PH) in dogs, yet there was no direct comparison of their hemodynamic effects.
- This study compared the effects of beraprost sodium (15 µg/kg), sildenafil (1.0 mg/kg), and their combination on dogs with induced mitral regurgitation using heart catheterization and echocardiography.
- Results showed that both drugs improved heart function, with sildenafil showing stronger pulmonary effects but also risking increased left-heart pressure; however, their combination provided the best overall results without negative impacts on heart size or pressure indicators.
Article Synopsis
- * The case study highlights an eight-month-old girl with a significant ASD and BPD-PH, where her pulmonary pressures were higher than systemic pressures, leading to a complicated right-to-left shunt.
- * After treating her with pulmonary preconditioning (dexamethasone and diuretics), the ASD was successfully closed, normalizing her heart pressures and improving oxygen saturation levels.
Effects of Beraprost with or without NOS Inhibition on Plasma Aldosterone and Hemodynamics in Healthy Cats.
Vet Sci
March 2024
Animal Medical Center, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan.
Objectives: The aim of the study was to evaluate the hemodynamic and RA system effects of the oral administration of the clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them.
Methods: A placebo-controlled pharmacological sequential design study was carried out to assess the plasma aldosterone and renin concentrations (PAC and PRC), blood pressure, heart rate, and exploratorily to estimate renal plasma flow (RPF) and renal vascular resistance (RVR) with simplified methods.
Results: Beraprost reduced PAC when compared to the placebo ( < 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!